Figure 1.

Connection between genetic and immunity in sarcomas and its translational relevance. STS dichotomization in simple and complex karyotypes does not reflect a sharp demarcation of immunogenicity and in situ immune infiltration. Along the characterization of patient- and tumor-related genetic alterations, the actual availability of high-throughput technologies has allowed immune profiling across and within distinct STS histologies. These analyses have highlighted previously unaddressed associations between genetic and/or epigenetic landscapes and peculiar immune contextures. From a translational point of view, while T cell-infiltrated STSs can benefit from immunotherapies, in T cell desert STSs, treatment by targeted or epigenetic drugs should be envisaged as therapeutic strategies to create a host environment potentially amenable to immunotherapies. Created with BioRender.com.